GLP-1 and Intestinal Diseases

被引：37
|
作者：
Hunt, Jenna Elizabeth [1 ]
Holst, Jens Juul [1 ,2 ]
Jeppesen, Palle Bekker [3 ]
Kissow, Hannelouise [1 ,2 ]
机构：
[1] Univ Copenhagen, Fac Hlth & Med Sci, Dept Biomed Sci, DK-2200 Copenhagen, Denmark
[2] Univ Copenhagen, Fac Hlth & Med Sci, Novo Nordisk Fdn, Ctr Basic Metab Res, DK-2200 Copenhagen, Denmark
[3] Rigshosp, Dept Med Gastroenterol & Hepatol, DK-2200 Copenhagen, Denmark
来源：
BIOMEDICINES | 2021年 / 9卷 / 04期
关键词：
GLP-1; intestinal disease; short-bowel syndrome (SBS); mucositis; inflammatory bowel disease (IBD); coeliac disease; GLUCAGON-LIKE PEPTIDE-1; INFLAMMATORY-BOWEL-DISEASE; RECEPTOR AGONISTS; GLYCEMIC CONTROL; KAPPA-B; PLASMA; CELLS; MECHANISMS; SECRETION; EXENATIDE;
D O I：
10.3390/biomedicines9040383
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Accumulating evidence implicates glucagon-like peptide-1 (GLP-1) to have, beyond glucose maintenance, a beneficial role in the gastrointestinal tract. Here, we review emerging data investigating GLP-1 as a novel treatment for intestinal diseases, including inflammatory bowel diseases, short-bowel syndrome, intestinal toxicities and coeliac disease. Possible beneficial mechanisms for these diseases include GLP-1 ' s influence on gastric emptying, its anti-inflammatory properties and its intestinotrophic effect. The current knowledge basis derives from the available GLP-1 agonist treatments in experimental animals and small clinical trials. However, new novel strategies including dual GLP-1/GLP-2 agonists are also in development for the treatment of intestinal diseases.
引用
收藏
页数：14
相关论文
共 50 条
  • [1] Endogenous GLP-1(7-36)amid (GLP-1):: Intestinal release and endocrine action in human
    Schirra, J
    Nicolaus, M
    Woerle, HJ
    Göke, B
    REGULATORY PEPTIDES, 2004, 122 (01) : 37 - 37
  • [2] Impaired Satiety Effect of GLP-1 Agonist in Obesity Is Associated With GLP-1 Resistance in Intestinal Afferent Nerves
    Al-Helaili, Alaa
    Wang, Beini
    Beyak, Michael
    GASTROENTEROLOGY, 2014, 146 (05) : S842 - S842
  • [3] Gastro-intestinal hormones GIP and GLP-1
    Kieffer, TJ
    ANNALES D ENDOCRINOLOGIE, 2004, 65 (01) : 13 - 21
  • [4] Endogenous GLP-1(7-36)amid (GLP-1): Intestinal release and endocrine action in human.
    Schirra, J
    Nicolaus, M
    Woerle, J
    Goeke, B
    GASTROENTEROLOGY, 2005, 128 (04) : A54 - A54
  • [5] The pleiotropic of GLP-1/GLP-1R axis in central nervous system diseases
    Zhang, LongQing
    Zhang, Wen
    Tian, XueBi
    INTERNATIONAL JOURNAL OF NEUROSCIENCE, 2021,
  • [6] The pleiotropic of GLP-1/GLP-1R axis in central nervous system diseases
    Zhang, LongQing
    Zhang, Wen
    Tian, XueBi
    INTERNATIONAL JOURNAL OF NEUROSCIENCE, 2023, 133 (05) : 473 - 491
  • [7] Intestinal CART is a regulator of GIP and GLP-1 secretion and expression
    Shcherbina, L.
    Lindqvist, A.
    Fischer, A-H Thoren
    Ahlqvist, E.
    Zhang, E.
    Falkmer, S. E.
    Renstrom, E.
    Koffert, J.
    Honka, H.
    Wierup, N.
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2018, 476 : 8 - 16
  • [8] Intestinal GLP-1 and satiation: from man to rodents and back
    Steinert, R. E.
    Beglinger, C.
    Langhans, W.
    INTERNATIONAL JOURNAL OF OBESITY, 2016, 40 (02) : 198 - 205
  • [9] Rate of intestinal glucose absorption and the secretion of GIP and GLP-1
    Priebe, MG
    Wachters-Hagedoorn, RE
    Holst, JJ
    Stellaard, F
    Vonk, RJ
    FASEB JOURNAL, 2005, 19 (04): : A74 - A74
  • [10] Fasting and postprandial concentrations of GLP-1 in intestinal lymph and portal plasma: evidence for selective release of GLP-1 in the lymph system
    D'Alessio, David
    Lu, Wendell
    Sun, William
    Zheng, Shuqin
    Yang, Qing
    Seeley, Randy
    Woods, Stephen C.
    Tso, Patrick
    AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 2007, 293 (06) : R2163 - R2169
12345